c-ret antikoerper, cret antikoerper, etID315074.13 antikoerper, ret1 antikoerper, wu:fd13h01 antikoerper, X-ret antikoerper, ret-A antikoerper, xret antikoerper, RET antikoerper, MTC1 antikoerper, CDHF12 antikoerper, CDHR16 antikoerper, HSCR1 antikoerper, MEN2A antikoerper, MEN2B antikoerper, PTC antikoerper, RET-ELE1 antikoerper, RET51 antikoerper, RET9 antikoerper, c-Ret antikoerper, ret proto-oncogene receptor tyrosine kinase antikoerper, ret proto-oncogene S homeolog antikoerper, ret proto-oncogene antikoerper, ret antikoerper, ret.S antikoerper, RET antikoerper, Ret antikoerper
Hintergrund
RET (ret proto-oncogene) is a member of the cadherin superfamily and a receptor tyrosine kinase, which are cell-surface molecules that transduce signals for cell growth and differentiation. It can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Ligands that bind the Ret receptor include the glial cell line-derived neurotropic factor (GDNF) and its congeners neurturin, persephin and artemin. Alterations in the corresponding Ret gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma and a congenital developmental disorder known as Hirschsprung? disease. The Tyr905 residue located in the Ret kinase domain plays a crucial role in Ret catalytic and biological activity. Substitution of Phe for Tyr905 dramatically inhibits Ret autophosphorylation activity.